Colloidal gold nanoparticles as a blood-pool contrast agent for x-ray computed tomography in mice

Investigative Radiology

Volumn 42, Issue 12, 2007, Pages 797-806

  Cai, Quan Yu ^a   Kim, Sun Hee ^a   Choi, Kyu Sil ^a   Kim, Soo Yeon ^a   Byun, Seung Jae ^a   Kim, Kyoung Woo ^a   Park, Seong Hoon ^a   Juhng, Seon Kwan ^a   Yoon, Kwon Ha ^a  

^a Wonkwang University School of Medicine   (South Korea)

Author keywords

AuNPs; Contrast agent; In vivo CT; Micro CT; X ray imaging

Indexed keywords

COLLOIDAL GOLD NANOPARTICLE PLUS MACROGOL; CONTRAST MEDIUM; MACROGOL; NANOCRYSTAL; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD POOL SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG UPTAKE; EMBRYO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; MATERIAL COATING; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 36249014870     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31811ecdcd     Document Type: Article

References (29)

1. Mattrey RF. Blood-pool contrast media are the ideal agents for computed tomography. Invest Radiol. 1991;26(suppl 1):S55-S56.
2. Brasch RC, Daldrup H, Shames D, et al. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. Acad Radiol. 1998;5(suppl 1):S2-S5.
3. Mattrey RF, Long DM, Multer F, et al. Perfluoroctylbromide: a reticuloendothelial-specific and tumor-imaging agent for computed tomography. Radiology. 1982;145:755-758.
4. Mattrey RF, Andre M, Campbell J, et al. Specific enhancement of intra-abdominal abscesses with perfluoroctylbromide for CT imaging. Invest Radiol. 1984;19:438-446.
5. Mattrey RF, Aguirre DA. Advances in contrast media research. Acad Radiol. 2003;10:1450-1460.
6. Badea CT, Fubara B, Hedlund LW, et al. 4-D micro-CT of the mouse heart. Mol Imaging. 2005;4:110-116.
7. Paulus MJ, Gleason SS, Kennel SJ, et al. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia. 2000;2:62-70.
8. Ritman EL. Micro-computed tomography-current status and developments. Annu Rev Biomed Eng. 2004;6:185-208.
9. Kiessling F, Greschus S, Lichy MP, et al. Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. Nat Med. 2004;10:1133-1138.
10. Wisner ER, Katzberg RW, Griffey SM, et al. Indirect computed tomography lymphography using iodinated nanoparticles: time and dose response in normal canine lymph nodes. Acad Radiol. 1995;2:985-993.
11. Weichert JP, Lee FT Jr, Chosy SG, et al. Combined hepatocyte-selective and blood-pool contrast agents for the CT detection of experimental liver tumors in rabbits. Radiology. 2000;216:865- 871.
12. Weichert JP, Lee FT Jr, Longino MA, et al. Lipid-based blood-pool CT imaging of the liver. Acad Radiol. 1998;5(suppl 1):S16-S19.
13. Vera DR, Mattrey RF. A molecular CT blood pool contrast agent. Acad Radiol. 2002;9:784-792.
14. Rabin O, Manuel PJ, Grimm J, et al. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006;5:118-122.
15. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004;11:169-183.
16. Chen J, Saeki F, Wiley BJ, et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett. 2005;5:473-477.
17. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49:N309-N315.
18. Hainfeld JF, Slatkin DN, Focella TM, et al. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79:248-253.
19. Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004;104:293-346.
20. Aryal S, B K C R, Dharmaraj N, et al. Spectroscopic identification of S-Au interaction in cysteine capped gold nanoparticles. Spectrochim Acta A Mol Biomol Spectrosc. 2006;63:160-163.
21. Gierada DS, Bae KT. Gadolinium as a CT contrast agent: assessment in a porcine model. Radiology. 1999;210:829-834.
22. Fournier LS, Cuenod CA, de BC, et al. Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. Eur Radiol. 2004;14:2125-2133.
23. Berthezene Y, Wiart M, Corot C, et al. CT pulmonary angiography and perfusion: an experimental study using blood pool and nonspecific contrast agent. Acad Radiol. 2002;9(suppl 2):S359-S360.
24. Ford NL, Graham KC, Groom AC, et al. Time-course characterization of the computed tomography contrast enhancement of an iodinated blood-pool contrast agent in mice using a volumetric flat-panel equipped computed tomography scanner. Invest Radiol. 2006;41:384-390.
25. Kobayashi H, Jo SK, Kawamoto S, et al. Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. J Magn Reson Imaging. 2004;20:512-518.
26. Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004;39:56-63.
27. Bourrinet P, Bengele HH, Bonnemain B, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006;41:313-324.
28. Briley-Saebo KC, Johansson LO, Hustvedt SO, et al. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism. Invest Radiol. 2006;41:560-571.
29. Chang JM, Lee JM, Lee MW, et al. Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol. 2006;41:168-174.